Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg

Key takeaways

• Eradicating both cancer and heart disease would extend average human lifespan by only 5 to 7 years, because underlying cellular decay continues unchecked. Read more →
• Biopharma's core delay is physical: synthesizing real atoms and culturing biological cells creates an expensive, slow trial-and-error cycle. Read more →
• Annual drug approvals have stayed roughly flat for decades, even as scientific publications, budgets, and therapeutic modalities grew exponentially. Read more →
• Rat models only predict human clinical toxicity roughly 30% of the time, leading to widespread failure when drug candidates reach human trials. Read more →
• True cross-disciplinary unicorns who master both frontier deep learning and wet-lab biochemistry do not exist in meaningful volume; companies must hire pure specialists from each camp and build fluency internally. Read more →